Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors. (17th November 2022)

• Record Type: Journal Article
• Authors: Thurau, Stephan; Engelke, Hendrik; McCluskey, Peter; Symes, Richard J.; Whist, Eline; Teuchner, Barbara; Haas, Gertrud; Allegri, Pia; Cimino, Luca; Bolletta, Elena; Miserocchi, Elisabetta; Russo, Marinella; Li, Jeany Q.; Heiligenhaus, Arnd; Wildner, Gerhild
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 7/8(2022)
• Page Start: 1588
• Page End: 1594
• Publication Date: 2022-11-17
• Subjects: Immune checkpoint inhibitors -- MEK inhibitor -- BRAF inhibitor -- autoimmune disease -- uveitis -- ocular inflammation -- eye; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2021.1910850
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Purpose: New tumor therapies like immune checkpoint inhibitors and small molecule inhibitors of MEK and BRAF have increased the patient's survival rate but can be burdened with severe side-effects including uveitis. Here, we show the spectrum, treatment, and outcome of uveitis types induced by tumor treatment. Methods: In this retrospective study, we have included 54 patients from different centers who were developing uveitis under tumor therapy. A 16-item questionnaire was analyzed for type, treatment, and outcome of uveitis and type of tumor treatment, which we have correlated here. Results: Irrespective of the tumor treatment, most patients developed anterior uveitis. All patients received corticosteroids and some additional immunosuppressive treatments. Cessation of tumor therapy was necessary only in a minority of cases. Conclusions: Ocular autoimmunity should be differentiated from toxic effects of cancer treatment and timely recognized since it can be generally well controlled by anti-inflammatory treatment, preserving the patient's vision without cessation of the tumor treatment.